-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Entecavir
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/142217-69-4.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 142217-69-4 |
| Description | An oral antiviral drug used in the treatment of hepatitis B infection. A guanine analogue that inhhibits all three steps in the viral replication process. |
Product Information
| Synonyms | Baraclude; BMS 200475; BMS-200475; BMS200475; SQ 34676; SQ34676; SQ-34676 |
| IUPAC Name | 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one |
| Molecular Weight | 277.284 |
| Molecular Formula | C12H15N5O3 |
| Canonical SMILES | C=C1C(CC(C1CO)O)N2C=NC3=C2NC(=NC3=O)N |
| InChI | InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1 |
| InChIKey | QDGZDCVAUDNJFG-FXQIFTODSA-N |
| Boiling Point | 734.2°C at 760 mmHg |
| Melting Point | 245-247 °C |
| Flash Point | 397.9°C |
| Purity | 0.98 |
| Density | 1.8±0.1 g/cm3 |
| Solubility | In Vitro: DMSO: ≥ 44 mg/mL (158.68 mM) |
| Appearance | White to Off-White Solid |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 480 |
| Exact Mass | 277.11748936 |
| Index Of Refraction | 1.837 |
| In Vitro | BMS-200475 has a EC50 of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses. Entecavir is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h. |
| In Vivo | Daily oral treatment with BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks. |
| PSA | 130.05000 |
| Target | EC50: 3.75 nM (anti-HBV, HepG2 cell) |
| XLogP3-AA | -1.3 |
